PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

News provided by

Feb 26, 2014, 06:04 ET

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02029821/PharmaPoint-Hemophilia-A-and-B---Global-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

Summary

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Several pharmaceutical companies, including Biogen Idec, Novo Nordisk, Bayer, Baxter and CSL Behring, will be launching long-acting rFVIII and rFIX therapies that aim to address this unmet need by providing increased protein half-life that potentially extends the time between prophylactic doses. The emergence of these new products, beginning in 2014 in the US and 2015 in the 5EU, will have a drastic effect on the hemophilia A and B treatment landscapes in the 7MM as patients adopt these premium-priced products. In the developing markets of Argentina and China, economic barriers prevent widespread adoption of recombinant prophylactic regimens, and pharmaceutical companies will face additional challenges in penetrating these markets during the forecast period.

Highlights

Key Questions Answered

- How will the launch of long-acting FVIII and FIX replacement products affect the hemophilia A and B recombinant treatment landscape?
- The emerging long-acting recombinant replacement therapies are poorly differentiated in terms of clinical benefit. How will launch timing affect patient adoption over the forecast period?
- The unmet needs of hemophilia A and B patients in the US and 5EU are relatively low. What unmet needs will remain after the launch of the long-acting factors?
- How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?
- The level of unmet needs for hemophilia patients in the developing markets of Argentina and China are higher compared to the established markets. Will the launch of long-acting products affect these markets? What additional opportunity will remain during the forecast period?

Scope

- Overview of hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized hemophilia A and B (including inhibitor patients) therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hemophilia therapeutics market
- Pipeline analysis: The hemophilia pipeline is robust, with many late-stage candidates set to launch in the forecast period. The most promising 12 candidates in Phase III development are highlighted and profiled.
- Analysis of the current and future market competition in the global hemophilia A and B markets, including insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B recombinant therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia recombinant therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Forecast drug sales in the global hemophilia recombinant therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 20

2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 25
3.1.3 Prognosis and Quality of Life 27
3.2 Symptoms 29
3.2.1 Hemophilia A and B 29
3.2.2 Inhibitors 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 32
4.2.1 Almost 50% of hemophilia patients are affected by hypertension 33
4.3 Global Trends 34
4.4 Epidemiological Forecast of Hemophilia (2012-2022) 36
4.4.1 Forecast Methodology 36
4.4.2 Sources Used 37

4.4.3 Sources Not Used 38
4.4.4 Forecast Assumptions and Methods 38
4.5 Epidemiology Forecast (2012-2022), Hemophilia A 43
4.5.1 Diagnosed Prevalent Cases of Hemophilia A 43
4.5.2 Diagnosed Prevalent Cases of Hemophilia A by Age 45
4.5.3 Diagnosed Prevalent Cases of Hemophilia A by Sex 47
4.5.4 Age-Standardized Prevalence of Diagnosed Hemophilia A 48
4.6 Epidemiology Forecast (2012-2022), Hemophilia B 50
4.6.1 Diagnosed Prevalent Cases of Hemophilia B 50
4.6.2 Diagnosed Prevalent Cases of Hemophilia B by Age 52
4.6.3 Diagnosed Prevalent Cases of Hemophilia B by Sex 54
4.6.4 Age-Standardized Prevalence of Diagnosed Hemophilia B 56
4.7 Epidemiology Forecast (2012-2022), Hemophilia A and B 57
4.7.1 Diagnosed Prevalent Cases of Hemophilia A and B 57
4.7.2 Diagnosed Prevalent Cases of Hemophilia A and B by Sex 59
4.8 Discussion 61
4.8.1 Conclusions on Epidemiological Trends 61
4.8.2 Limitations of the Analysis 62
4.8.3 Strengths of the Analysis 63
5 Disease Management 64
5.1 Treatment Overview 64
5.1.1 Hemophilia A and B Diagnosis 65
5.1.2 Hemophilia A and B Treatment 65
5.1.3 Inhibitors Diagnosis 67
5.1.4 Inhibitors Treatment 67
5.2 US 69
5.2.1 Clinical Practice 69
5.3 France 72

5.3.1 Clinical Practice 72
5.4 Germany 74
5.4.1 Clinical Practice 74
5.5 Italy 76
5.5.1 Clinical Practice 76
5.6 Spain 78
5.6.1 Clinical Practice 78
5.7 UK 80
5.7.1 Clinical Practice 80
5.8 Japan 82
5.8.1 Clinical Practice 82
5.9 Argentina 84
5.9.1 Clinical Practice 84
5.10 China 86
5.10.1 Clinical Practice 86
6 Competitive Assessment 88
6.1 Overview 88
6.2 Strategic Competitive Assessment 89
6.3 Product Profiles - Major Brands, Hemophilia A 93
6.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 93
6.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 98
6.3.3 Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free) 103
6.3.4 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 107
6.4 Product Profiles - Hemophilia B 110
6.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 110
6.4.2 Rixubis (BAX-326) 115
6.5 Product Profiles - Hemophilia A and B with Inhibitors 120
6.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 120
7 Opportunity and Unmet Need 123
7.1 Overview 123
7.2 Opportunities Analysis 124
7.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 124
7.2.2 Lower-Cost Recombinant Replacement Therapies 125
7.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 126
7.2.4 More Convenient Drug Administration 126
7.2.5 Oral Formulation of Recombinant Replacement Therapies 127
7.3 Unmet Needs Gap Analysis 128
7.3.1 Long-Acting FVIII Replacement Therapies 128
7.3.2 Gene Therapy Treatments for Hemophilia A and B 128
8 Pipeline Assessment 129
8.1 Overview 129
8.2 Clinical Trial Mapping 129
8.2.1 Clinical Trials by Country 129
8.3 Clinical Trials by Phase and Trial Status 130
8.4 Promising Drugs in Clinical Development - Hemophilia A 131

8.4.1 Eloctate (rFVIII-Fc) (recombinant factor VIII fusion protein) 133
8.4.2 BAY 94-9027 (octocog alfa) 140
8.4.3 BAX-855 145
8.4.4 Novoeight (turoctocog alfa; NN7008) 150
8.4.5 N8-GP (NN7088) 155
8.4.6 CSL-627 (rFVIII-SC) 160
8.4.7 Hcl-rhFVIII 165
8.5 Promising Drugs in Clinical Development - Hemophilia B 170
8.5.1 Alprolix (rFIXFc) 172
8.5.2 CSL-654 (rIX-FP) 177
8.5.3 N9-GP (NN-7999) 182
8.5.4 IB1001 (trenacog alfa) 187
8.6 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors 192
8.6.1 BAX-817 (rFVIIa BI) 192
9 Current and Future Players 197
9.1 Overview 197
9.2 Trends in Corporate Strategy 199
9.3 Company Profiles 200
9.3.1 Baxter 200
9.3.2 Biogen Idec 204
9.3.3 Novo Nordisk 206
9.3.4 CSL Behring 209
9.3.5 Bayer 210
9.3.6 Pfizer 212
10 Market Outlook 214
10.1 Global Markets 214
10.1.1 Forecast 214

10.1.2 Drivers and Barriers - Global Issues 218
10.2 US 221
10.2.1 Forecast 221
10.2.2 Key Events 225
10.2.3 Drivers and Barriers 225
10.3 France 228
10.3.1 Forecast 228
10.3.2 Key Events 231
10.3.3 Drivers and Barriers 231
10.4 Germany 233
10.4.1 Forecast 233
10.4.2 Key Events 236
10.4.3 Drivers and Barriers 236
10.5 Italy 238
10.5.1 Forecast 238
10.5.2 Key Events 241
10.5.3 Drivers and Barriers 241
10.6 Spain 243
10.6.1 Forecast 243
10.6.2 Key Events 246
10.6.3 Drivers and Barriers 246
10.7 UK 248
10.7.1 Forecast 248
10.7.2 Key Events 251
10.7.3 Drivers and Barriers 251
10.8 Japan 254
10.8.1 Forecast 254
10.8.2 Key Events 257

10.8.3 Drivers and Barriers 257
10.9 Argentina 259
10.9.1 Forecast 259
10.9.2 Key Events 263
10.9.3 Drivers and Barriers 263
10.10 China 266
10.10.1 Forecast 266
10.10.2 Key Events 269
10.10.3 Drivers and Barriers 269
11 Appendix 271
11.1 Bibliography 271
11.2 Abbreviations 287
11.3 Methodology 290
11.4 Forecasting Methodology 290
11.4.1 Diagnosed Hemophilia Patients 291
11.4.2 Percent Drug-Treated Patients 291
11.4.3 Drugs Included in Each Therapeutic Class 291
11.4.4 Launch and Patent Expiry Dates 292
11.4.5 General Pricing Assumptions 293
11.4.6 Individual Drug Assumptions 294
11.4.7 Pricing of Pipeline Agents 298
11.5 Physicians and Specialists Included in this Study 299
11.6 About the Authors 301
11.6.1 Authors 301
11.6.2 Epidemiologists 302
11.6.3 Global Head of Healthcare 303
11.7 About GlobalData 304
11.8 Disclaimer 304

List of Tables

Table 1: Symptoms of Hemophilia A and B 30
Table 2: Relationship of Bleeding Severity with Clotting Factor Level 31
Table 3: 9MM, Prevalence of Hemophilia A in Men (per 100,000 Population), All Ages, 1998-2006 35
Table 4: 9MM, Prevalence of Hemophilia B in Men (per 100,000 Population), All Ages, 1998-2006 35
Table 5: 9MM, Sources of Hemophilia A and Hemophilia B Prevalence Data 36
Table 6: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2012-2022 43
Table 7: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, Row (%), 2012 45
Table 8: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, Row (%), 2012 47
Table 9: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2012-2022 50
Table 10: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, Row (%), 2012 52
Table 11: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, Row (%), 2012 54
Table 12: 9MM, Diagnosed Prevalent Cases of Hemophilia, Both Sexes, All Ages, N, 2012-2022 57
Table 13: 9MM, Diagnosed Prevalent Cases of Hemophilia A and B, by Sex, All Ages, N, Row (%), 2012 59
Table 14: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2013 68
Table 15: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2013 91
Table 16: Leading Plasma-Based Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2012 92
Table 17: Product Profile - Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 94
Table 18: Advate SWOT Analysis, 2013 96
Table 19: Global Sales Forecasts ($m) for Advate, 2012-2022 97
Table 20: Product Profile - Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 99
Table 21: Kogenate FS/Helixate FS SWOT Analysis, 2013 101
Table 22: Global Sales Forecast ($m) for Kogenate FS/Kogenate Bayer, 2012-2022 102
Table 23: Global Sales Forecast ($m) for Helixate FS/Helixate NexGen, 2012-2022 102

Table 24: Product Profile - Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free) 104
Table 25: Xyntha/ReFacto AF SWOT Analysis, 2013 105
Table 26: Global Sales Forecast ($m) for Xyntha AF/ReFacto AF, 2012-2022 106
Table 27: Product Profile - Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 107
Table 28: Recombinate SWOT Analysis, 2013 108
Table 29: Global Sales Forecast ($m) for Recombinate, 2012-2022 109
Table 30: Product Profile - BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 111
Table 31: BeneFIX SWOT Analysis, 2013 113
Table 32: Global Sales Forecast ($m) for BeneFIX, 2012-2022 114
Table 33: Product Profile - Rixubis (BAX-326) 116
Table 34: Rixubis SWOT Analysis, 2013 118
Table 35: Global Sales Forecast ($m) for Rixubis, 2012-2022 119
Table 36: Product Profile - NovoSeven RT (coagulation factor VIIa [recombinant]) 120
Table 37: NovoSeven RT SWOT Analysis, 2013 121
Table 38: Global Sales Forecast ($m) for NovoSeven, 2012-2022 122
Table 39: Overall Unmet Needs - Current Level of Attainment 124
Table 40: Hemophilia A and B - Clinical Trials by Phase and Status, 2013 130
Table 41: Hemophilia A - Phase I/II Pipeline, 2013 131
Table 42: Hemophilia A - Phase III Pipeline, 2013 131
Table 43: Product Profile - Eloctate (rFVIII-Fc) 134
Table 44: Eloctate SWOT Analysis, 2013 138
Table 45: Global Sales Forecast ($m) for Eloctate, 2012-2022 139
Table 46: Product Profile - BAY 94-9027 140
Table 47: BAY 94-9027 SWOT Analysis, 2013 143
Table 48: Global Sales Forecast ($m) for BAY 94-9027, 2012-2022 144
Table 49: Product Profile - BAX-855 145
Table 50: BAX-855 SWOT Analysis, 2013 148
Table 51: Global Sales Forecast ($m) for BAX-855, 2012-2022 149
Table 52: Product Profile - Novoeight (turoctocog alfa; NN7008) 150
Table 53: Novoeight SWOT Analysis, 2013 153
Table 54: Global Sales Forecast ($m) for Novoeight, 2012-2022 154
Table 55: Product Profile - N8-GP (NN7088) 155
Table 56: N8-GP SWOT Analysis, 2013 158
Table 57: Global Sales Forecast ($m) for N8-GP, 2012-2022 159
Table 58: Product Profile - CSL-627 (rFVIII-SC) 160

Table 59: CSL-627 SWOT Analysis, 2013 163
Table 60: Global Sales Forecast ($m) for CSL-627, 2012-2022 164
Table 61: Product Profile - hcl-rhFVIII 165
Table 62: hcl-rhFVIII SWOT Analysis, 2013 168
Table 63: Global Sales Forecast ($m) for hcl-rhFVIII, 2012-2022 169
Table 64: Hemophilia B - Phase I/II Pipeline, 2013 170
Table 65: Hemophilia B - Phase III Pipeline, 2013 170
Table 66: Product Profile - Alprolix (rFIXFc) 172
Table 67: Alprolix SWOT Analysis, 2013 175
Table 68: Global Sales Forecast ($m) for Alprolix, 2012-2022 176
Table 69: Product Profile - CSL-654 177
Table 70: CSL-654 SWOT Analysis, 2013 180
Table 71: Global Sales Forecast ($m) for CSL-654, 2012-2022 181
Table 72: Product Profile - N9-GP 182
Table 73: N9-GP SWOT Analysis, 2013 185
Table 74: Global Sales Forecast ($m) for N9-GP, 2012-2022 186
Table 75: Product Profile - IB1001 188
Table 76: IB1001 SWOT Analysis, 2013 190
Table 77: Global Sales Forecast ($m) for IB1001, 2012-2022 191
Table 78: Hemophilia A and B with Inhibitors - Phase I/II Pipeline, 2013 192

Table 79: Hemophilia A and B with Inhibitors - Phase III Pipeline, 2013 192
Table 80: Product Profile - BAX-817 (rFVIIa BI) 193
Table 81: BAX-817 SWOT Analysis, 2013 195
Table 82: Global Sales Forecast ($m) for BAX-817, 2012-2022 196
Table 83: Key Companies in the Hemophilia A and B Market, 2013 198
Table 84: Baxter's Hemophilia Portfolio Assessment, 2013 202
Table 85: Baxter SWOT Analysis, 2013 203
Table 86: Biogen Idec's Hemophilia Portfolio Assessment, 2013 205
Table 87: Biogen SWOT Analysis, 2013 205
Table 88: Novo Nordisk's Hemophilia Portfolio Assessment, 2013 207
Table 89: Novo Nordisk SWOT Analysis, 2013 208
Table 90: CSL Behring's Hemophilia Portfolio Assessment, 2013 209
Table 91: CSL Behring SWOT Analysis, 2013 210
Table 92: Bayer's Hemophilia Portfolio Assessment, 2013 211
Table 93: Bayer SWOT Analysis, 2013 211
Table 94: Pfizer's Hemophilia Portfolio Assessment, 2013 212
Table 95: Pfizer SWOT Analysis, 2013 213
Table 96: Sales Forecasts ($m) for Hemophilia A and B in the 9MM, 2012-2022 216
Table 97: Global Hemophilia A and B Market - Drivers and Barriers, 2013 218
Table 98: Sales Forecasts ($m) for Hemophilia A and B in the US, 2012-2022 223
Table 99: Key Events Impacting Sales for Hemophilia A and B in the US, 2013 225
Table 100: US Hemophilia A and B Market - Drivers and Barriers, 2013 225
Table 101: Sales Forecasts ($m) for Hemophilia A and B in France, 2012-2022 229
Table 102: Key Events Impacting Sales for Hemophilia A and B in France, 2013 231
Table 103: French Hemophilia A and B Market - Drivers and Barriers, 2013 231
Table 104: Sales Forecasts ($m) for Hemophilia A and B in Germany, 2012-2022 234
Table 105: Key Events Impacting Sales for Hemophilia A and B in Germany, 2013 236
Table 106: German Hemophilia A and B Market - Drivers and Barriers, 2013 236

Table 107: Sales Forecasts ($m) for Hemophilia A and B in Italy, 2012-2022 239
Table 108: Key Events Impacting Sales for Hemophilia A and B in Italy, 2013 241
Table 109: Italian Hemophilia A and B Market - Drivers and Barriers, 2013 241
Table 110: Sales Forecasts ($m) for Hemophilia A and B in Spain, 2012-2022 244
Table 111: Key Events Impacting Sales for Hemophilia A and B in Spain, 2013 246
Table 112: Spanish Hemophilia A and B Market - Drivers and Barriers, 2013 246
Table 113: Sales Forecasts ($m) for Hemophilia A and B in the UK, 2012-2013 249
Table 114: Key Events Impacting Sales for Hemophilia A and B in the UK, 2013 251
Table 115: UK Hemophilia A and B Market - Drivers and Barriers, 2013 251
Table 116: Sales Forecasts ($m) for Hemophilia A and B in Japan, 2012-2022 255
Table 117: Key Events Impacting Sales for Hemophilia A and B in Japan, 2013 257
Table 118: Japanese Hemophilia A and B Market - Drivers and Barriers, 2013 257
Table 119: Sales Forecasts ($m) for Hemophilia A and B in Argentina, 2012-2022 261
Table 120: Key Events Impacting Sales for Hemophilia A and B in Argentina, 2013 263
Table 121: Argentine Hemophilia A and B Market - Drivers and Barriers, 2013 263
Table 122: Sales Forecasts ($m) for Hemophilia A and B in China, 2012-2022 267
Table 123: Key Events Impacting Sales for Hemophilia A and B in China, 2013 269
Table 124: Chinese Hemophilia A and B Market - Drivers and Barriers, 2013 269
Table 125: Key Launch Dates 292
Table 126: Physicians Surveyed 299

1.2 List of Figures
Figure 1: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2012-2022 44
Figure 2 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, 2012 46
Figure 3: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, 2012 48
Figure 4: 9MM, Age-Standardized Prevalence of Diagnosed Hemophilia A (per 100,000 Population), by Sex, 2012 49
Figure 5: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2012-2022 51
Figure 6: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, 2012 53
Figure 7: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, 2012 55
Figure 8: 9MM, Age-Standardized Prevalence of Diagnosed Hemophilia B (per 100,000 Population), by Sex, 2012 56
Figure 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A and B, Both Sexes, All Ages, N, 2012-2022 58
Figure 10: 9MM, Diagnosed Prevalent Cases of Hemophilia A and B, by Sex, All Ages, N, 2012 60
Figure 11: Hemophilia A and B Therapeutics - Clinical Trials by Country, 2013 129
Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2012-2022 132
Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia B, 2012-2022 171
Figure 14: Company Portfolio Gap Analysis in Hemophilia A and B, 2012-2022 198
Figure 15: Global Sales for Hemophilia A and B by Region, 2012-2022 217
Figure 16: Sales for Hemophilia A and B in the US by Drug Class, 2012-2022 224
Figure 17: Sales for Hemophilia A and B in France by Drug Class, 2012-2022 230
Figure 18: Sales for Hemophilia A and B in Germany by Drug Class, 2012-2022 235
Figure 19: Sales for Hemophilia A and B in Italy by Drug Class, 2012-2022 240
Figure 20: Sales for Hemophilia A and B in Spain by Drug Class, 2012-2022 245
Figure 21: Sales for Hemophilia A and B in the UK by Drug Class, 2012-2022 250
Figure 22: Sales for Hemophilia A and B in Japan by Drug Class, 2012-2022 256
Figure 23: Sales for Hemophilia A and B in Argentina by Drug Class, 2012-2022 262
Figure 24: Sales for Hemophilia A and B in China by Drug Class, 2012-2022 268